Latest Conference Articles

Elizabeth A. Mittendorf, MD, PhD, discusses the immunotherapy combinations currently being investigated in the treatment of breast cancer.

Kimberly Blackwell, MD,&nbsp;discusses the results of the recent phase III OLYMPIAD trial, which showed olaparib (Lynparza) improved progression-free survival (PFS) versus standard chemotherapy in patients with <em>BRCA</em>-positive breast cancer.

Kelly K. Hunt, MD, professor of Surgery, and chair, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses incorporating biologic factors into breast cancer staging.

Hope Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses targeting the androgen receptor in breast cancer.

The addition of CDK4/6 and mTOR inhibitors to standard endocrine therapy has significantly improved outcomes in patients with hormone receptor (HR)&ndash;positive, HER2-negative advanced breast cancer.

Larry Norton, MD, says the so-called butterfly effect, in which a small creature can cause something on the scale of an earthquake merely by flapping its wings, is fodder for debate on whether the digital revolution in medicine can deliver on its promise for precision medicine.

Pat Whitworth, MD, discusses how surgeons remain involved in genetic counseling to meet the immense unmet need that exists for patients with breast cancer.

Adam M. Brufsky, MD, PhD, discusses considerations for using denosumab as well as zoledronic acid as in patients with breast cancer.

The addition of the CDK4/6 inhibitor ribociclib to frontline letrozole reduced the risk of disease progression or death by 40% in elderly patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Combining eribulin with pembrolizumab for patients with metastatic triple-negative breast cancer demonstrated promising objective response rates, including a complete response, according to findings from a phase Ib/II study presented at the 2017 Miami Breast Cancer Conference.

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the link between circulating tumor cells and survival outcomes in metastatic breast cancer.

John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses studies investigating pacritinib for the treatment of myelofibrosis.

Worldwide clinical experience with the JAK1/2 inhibitor ruxolitinib in patients with myelofibrosis has yielded safety and efficacy data similar to results of a pivotal randomized trial.

Treating patients with intermediate/high-risk myelofibrosis with the Janus kinase inhibitor ruxolitinib long-term demonstrated improved survival, pooled data from 2 randomized trials showed.

An international patient survey showed patients with myeloproliferative disorders have a high symptom burden that significantly affects emotional status, quality of life, and functional ability.

The addition of ADI-PEG 20, a pegylated form of an arginine-depleting enzyme, to nab-paclitaxel and gemcitabine has encouraging activity in patients with advanced pancreatic adenocarcinoma while demonstrating minimal additional toxicity over that with cytotoxic therapy alone.

<span style="font-size:12px">Treatment administration and supportive care costs were significantly higher for patients with metastatic pancreatic cancer who were treated with FOLFIRINOX as first-line therapy compared with the combination of nab-paclitaxel and gemcitabine.</span>

A gemcitabine-free regimen resulted in numerically better survival compared with a conventional gemcitabine regimen in patients with metastatic pancreatic cancer, results of a randomized trial showed.

Overall survival was improved and disease progression was slowed in patients with metastatic pancreatic ductal adenocarcinoma when nanoliposomal irinotecan was added to 5-fluorouracil and leucovorin, irrespective of treatment history, a posthoc analysis of a randomized trial showed.

Mark S. Talamonti, MD, clinical professor, NorthShore University HealthSystem, discusses the current and future role of minimally invasive surgery in pancreatic cancer.

Gabriela Chiorean, MD, professor of medicine, discusses an ongoing phase I study of nivolumab with nab-paclitaxel plus gemcitabine in pancreatic cancer.

Adding a platinum to standard gemcitabine and nab-paclitaxel led to impressive responses and overall survival rates in a small pilot trial in patients with stage IV pancreatic cancer.

CCX872-B, a potent, selective oral inhibitor of CCR2, added to FOLFIRINOX was associated with a tumor control rate of 78% at week 12 in a single-arm study of patients with locally advanced or metastatic pancreatic cancer.

Encouraging clinical activity with limited toxicity in patients with metastatic pancreatic cancer will lead to further evaluation of nivolumab plus nab-paclitaxel with gemcitabine, investigators reported at the Gastrointestinal Cancers Symposium in San Francisco.

Engaging in moderate physical activity daily was shown to reduce mortality and cancer progression&nbsp;in patients with metastatic colorectal cancer.

Patients with malignant gastric outlet obstruction who received surgical palliation maintained their quality of life and improved solid food intake for at least 3 months after surgery.

A novel combination regimen of ramucirumab plus pembrolizumab demonstrated modest activity in patients with previously treated gastric or gastroesophageal juncture cancer.

Ian Chau, MD, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab.

A watch-and-wait approach is emerging as a potential treatment strategy for patients with rectal cancer, according to the results of real-world data from a large observational study .

Pathologic complete response (pCR) rates were improved by switching neoadjuvant chemotherapy regimens based on PET imaging after induction chemotherapy in patients with esophageal and gastroesophageal junction (GEJ) cancers, according to findings from the phase II CALGB 80803 study.